Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mouse Study Turns T Cells into Liver Cancer Treatment

By Kenny Walter | April 3, 2018

After exposing genetically manipulated mice to respond to a common antigen found in human liver cancer, Georgia Cancer Center scientists believe they can turn T cells into fighters against the disease.

The researchers studied mice engineered to express the human leukocyte antigen, which helps regulate the immune system. The antigen helped the mice produce the powerful T cells against liver cancer.

The researchers immunized the mice with the antigen α-fetoprotein, which is found in 70 to 80 percent of human liver cancers, and serves as both a biomarker for diagnosing and a target for treating the sixth most common cancer worldwide.

“For the T cell to recognize the tumor cell, it has to have a receptor for that tumor cell,” corresponding author Yukai He, PhD, an immunologist at the Georgia Cancer Center and Department of Medicine at the Medical College of Georgia at Augusta University, said in a statement.

In the study, the team took the genes for the most effective liver cancer antigen receptors on the T cells and put the receptors on human T cells. This resulted in engineered human T cells that eradicated the cancer without hurting normal liver cells.

“These T cells are very potent and can kill human liver cancer both in a dish and in a mouse,” He said.

The researchers found that large human liver cancer tumors on comparatively small mice, started regressing approximately 20 days after treatment and were eradicated by the 41st day with the aid of one of the targeted receptors.

“Now that we have these T cell receptor genes, we may be able to humanize the genes to help patients,” He said.

T cells have receptors that recognize infections or cancers, but the drivers of the immune response is often not as effective at attacking cancer. This is likely because cancer cells are mostly a mutation of a person’s own cells.

“Most cancers are self-antigens,” He said. “Our body’s immune cells are not supposed to fight them, otherwise it becomes autoimmune disease.” 

He will now collaborate with the Piedmont Atlanta Hospital to retrieve T cells, liver cancer cells and healthy tissue normally removed from patients during surgery, put the mouse receptor genes on the T cells, monitor in a dish to see how the cells fight the tumor, and react to healthy human tissue.

If the engineered human T cells do produce a robust cancer attack and do not generate toxicity by also attacking healthy cells, the researchers would then conduct clinical trials.

Newer cancer treatments, like adoptive T cell therapy, use a variety of ways to strengthen T cells for the fight and He said the mouse receptor genes could be another way to do that.

According to the US Centers for Disease Control and Prevention, rates of new liver cancer increased 38 percent from 2003 to 2012. Nearly 23,000 people died from liver cancer in 2012, representing a 56 percent increase in deaths from 2003. Men died from liver cancer at more than twice the rate of women.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE